Leena Helle

Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer

Heikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, Petri Bono et al. · New England Journal of Medicine · 2006 · 1.4K citations

Medicine, Oncology, Pharmacology +16

Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial

Heikki Joensuu, Petri Bono, Vesa Kataja et al. · Journal of Clinical Oncology · 2009 · 459 citations · Full text

Medicine, Oncology, Pharmacology +17

Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial

Heikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, Riikka Huovinen et al. · Journal of Clinical Oncology · 2011 · 118 citations · Full text

Medicine, Oncology, Pharmacology +17

Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial

Heikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, Riikka Huovinen et al. · The Lancet Oncology · 2009 · 64 citations

Medicine, Oncology, Pharmacology +14

Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration.

Carl Blomqvist, Inkeri Elomaa, P Rissanen et al. · Journal of Clinical Oncology · 1993 · 53 citations

Medicine, Oncology, Pharmacology +17